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Abstract Despite more than 50 years of vaccination, pertus-
sis is still an endemic disease, with regular epidemic out-
breaks. With the exception of Poland, European countries
have replaced whole-cell vaccines (WCVs) by acellular vac-
cines (ACVs) in the 1990s. Worldwide, antigenic divergence
in vaccine antigens has been found between vaccine strains
and circulating strains. In this work, 466 Bordetella pertussis
isolates collected in the period 1998–2012 from 13 European
countries were characterised by multi-locus antigen sequence
typing (MAST) of the pertussis toxin promoter (ptxP) and of
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the genes coding for proteins used in the ACVs: pertussis
toxin (Ptx), pertactin (Prn), type 2 fimbriae (Fim2) and type
3 fimbriae (Fim3). Isolates were further characterised by fim-
brial serotyping, multi-locus variable-number tandem repeat
analysis (MLVA) and pulsed-field gel electrophoresis (PFGE).
The results showed a very similar B. pertussis population for
12 countries using ACVs, while Poland, which uses a WCV,
was quite distinct, suggesting that ACVs andWCVs select for
different B. pertussis populations. This study forms a baseline
for future studies on the effect of vaccination programmes on
B. pertussis populations.
Introduction
Pertussis, or whooping cough, is a highly contagious human
infection of the upper respiratory tract caused by the Gram-
negative bacterium Bordetella pertussis [1]. Despite the intro-
duction of vaccination against pertussis more than 50 years
ago, the disease is still a public health problem worldwide,
with epidemic outbreaks occurring every 3–5 years. In the last
10 years, a resurgence of pertussis was observed in countries
with highly vaccinated populations, including Australia [2],
Norway [3], Poland [4], the Netherlands [5], the United King-
dom [6] and the United States [7]. One of the hallmarks of the
pertussis resurgence is the shift in prevalence from young
infants to older persons with waning vaccine-induced immu-
nity [8, 9]. Several causes have been proposed for the resur-
gence of pertussis, including improved diagnosis, increased
awareness [10, 11], decreased vaccine efficacy, waning im-
munity and pathogen adaptation [12, 13]. The contribution of
these factors to the resurgence of pertussis may differ between
countries.
European countries use different vaccines and vaccination
schedules for pertussis (Table 1 and http://vaccine-schedule.
ecdc.europa.eu/Pages/Scheduler.aspx). Partly due to the side
effects of the whole-cell vaccines (WCVs), all European
countries, except Poland, have replaced WCVs by acellular
vaccines (ACVs) since the 1990s [14]. WCVs are composed
of killed B. pertussis bacteria, while ACVs consist of 1–5
purified B. pertussis proteins: pertussis toxin (Ptx), pertactin
(Prn), filamentous haemagglutinin (FHA), type 2 fimbriae
(Fim2) and type 3 fimbriae (Fim3). Worldwide, variation in
these vaccine antigens have been found between strains used
for the production of the vaccines and isolates that are circu-
lating in those countries where these vaccines have been used
extensively [2, 15–25].
Besides antigenic variation, recently, B. pertussis isolates
have emerged which produce higher levels of a number of
virulence factors in vitro, including Ptx [5, 26]. These isolates
carry a new allele for the Ptx promoter, ptxP3, and have
replaced the resident ptxP1 isolates in many countries. The
emergence of ptxP3 isolates is associated with the increase in
pertussis notifications in the Netherlands since 1996 [5].
Nowadays, ptxP3 isolates are found worldwide [20–22, 25,
27–30]. Moreover, recently, B. pertussis isolates have been
observed that do not express one or more vaccine compo-
nents, in particular, Prn [7, 31–39].
Monitoring changes in the European B. pertussis popula-
tions and studying the impact of these changes on the disease
burden are important in order to establish the most effective
pertussis vaccines and vaccination strategies. To study these
changes, a European network, designated EUpertstrain, was
created in 2001, with the main aim of collecting and typing of
European B. pertussis isolates. The number of participating
countries increased from five in 2001 to nine in 2013 [40–43].
Members of the EUpertstrain group collected and typed iso-
lates on a regular basis between 2001 and 2013. Typing
involved multi-locus antigen sequence typing (MAST), fim-
brial serotyping, multi-locus variable-number tandem repeat
analysis (MLVA) and pulsed-field gel electrophoresis (PFGE).
However, direct comparison of these isolates collected during
the study period was only performed by PFGE analyses
[41–43].
This present study is part of a European Centre for Disease
Control and Prevention (ECDC)-funded network, EUpert-
labnet, which focuses on the laboratory surveillance of
whooping cough in EU Member States and European Eco-
nomic Area (EEA) countries. In this study, we present the
typing results of isolates collected from 13 countries
Table 1 Pertussis vaccines currently used in European countries*
Country Vaccine
Belgium ACV3
Czech Republic ACV3 or ACV5
Denmark ACV1
Finland ACV2 or ACV3
France ACV2, ACV3 or ACV5
Germany ACV2 or ACV3
Ireland ACV3
Norway ACV3
Poland WCV
Spain ACV3
Sweden ACV2 or ACV3
The Netherlands ACV3
United Kingdom ACV3 or ACV5
*Vaccine compositions: ACV1: Ptx; ACV2: Ptx and FHA; ACV3: Ptx,
FHA and Prn; ACV5: Ptx, FHA, Prn, Fim2 and Fim3
J. Mertsola
Department of Pediatrics, Turku University Hospital, Turku, Finland
A. Economopoulou
European Centre for Disease Control and Prevention (ECDC),
Stockholm, Sweden
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(Belgium, the Czech Republic, Denmark, Finland, France,
Germany, Ireland, Norway, Poland, Spain, Sweden, the Neth-
erlands and the United Kingdom) between 2000 and 2012.
Further, the typing of previous collections was extended and
the results were combined to give an overview of B. pertussis
isolates circulating in European countries between 1998 and
2012.
Materials and methods
B. pertussis isolates
B. pertussis isolates were grown on Bordet–Gengou (BG)
agar with 15 % sheep blood and incubated for 3 to 4 days at
35 °C. In total, 466 B. pertussis isolates were included in this
study (Supplementary Table S1). Isolates collected between
1998 and 2009 were previously analysed by PFGE [41–43].
Here, we extended these analyses by typing more isolates
from this period. Further, we present novel data from five
EU countries; Belgium (n=20, isolated in 2000–2012), the
Czech Republic (n=20, isolated in 2008–2012), Ireland (n=
20, isolated in 2003–2012), Poland (n=20, isolated in 2000–
2012) and Spain (n=12, isolated in 2004–2012).
Multi-locus antigen sequence typing (MAST)
Polymorphisms in the genes for proteins used in the ACVs
(PtxA, Prn, Fim2 and Fim3) were analysed as described
previously [5, 15, 44, 45]. The pertussis toxin promoter, ptxP,
was also included, as previous studies have shown that the
ptxP3 allele is an important characteristic of successful iso-
lates [5, 20–22, 25, 27–30]. For DNA isolation, bacterial cells
were lysed in Tris-EDTA buffer (Sigma-Aldrich, Zwijndrecht,
the Netherlands, 1.0 M Tris–HCl, containing 0.1 M EDTA,
100× concentrated) at 95 °C for 5 min, centrifuged briefly and
used in a polymerase chain reaction (PCR) assay.
Serotyping
A bacterial suspension was mixed on a glass slide with mono-
clonal or polyclonal antibodies against Fim2 or Fim3 (Nation-
al Institute for Biological Standards and Control (NIBSC),
South Mimms, UK). Agglutination was determined after a
maximum of 30 s to avoid false-positive agglutination [44].
Bacterial suspensions were mixed with a physiological salt
solution to determine auto-agglutination.
Multi-locus variable-number tandem repeat analysis (MLVA)
For MLVA, the variable number of tandem repeats in six loci
(VNTR1, VNTR3a, VNTR3b, VNTR4, VNTR5 and
VNTR6) was determined as described previously [23, 46].
Pulsed-field gel electrophoresis (PFGE)
All EUpertstrain isolates were previously analysed by PFGE
at the Swedish Institute for Communicable Disease Control
(SMI) [43]. PFGE of isolates from Belgium, Ireland and
Poland was performed by the respective countries, whereas
PFGE of isolates from the Czech Republic and Spain was
performed at the Finnish National Institute for Health and
Welfare (THL). Gel images of all isolates from the five coun-
tries were also analysed at the Finnish THL. The PFGE
protocol, reference strains used and profile analysis were the
same as those previously described [43]. The profiles were
analysed by using BioNumerics software version 4.61 (Ap-
plied Maths, Sint-Martens-Latem, Belgium). The Swedish
nomenclature was used and based on cluster analysis with
the group method with 1 % band tolerance and 1 % optimi-
sation settings. The resulting profiles were designated BpSR1,
BpSR2, BpSR3 etc. for those isolates with profiles first de-
tected in Sweden. Isolates first identified in a country other
than Sweden, such as Finland, were designated BpFINR1,
BpFINR2 etc.
Results
The EUpertstrain and EUpert-labnet collections
One of the aims of the EUpertstrain network is to collect
isolates from different European countries in order to assess
the emergence and spread of new variants of B. pertussis. A
secondary aim is to determine the effect, if any, of different
vaccination strategies on the pertussis burden and the emer-
gence of new variants. Analyses of the three EUpertstrain
collections isolated between 1998 and 2009 by PFGE and
analysis of the EUpert I collection isolated between 1998 and
2001 by MLVA have already been published [40–43].
Here, we extend this work to the EUpert-labnet collection
by including five more EU countries: Belgium, the Czech
Republic, Ireland, Poland and Spain (Table 2). Further, addi-
tional typing was performed on previously collected isolates.
The old and new data were integrated to give an overview of
(country-specific) changes of the B. pertussis populations in
the participating European countries. Isolates collected be-
tween 1998 and 2012 were aggregated in three periods to
obtain a comparable number of isolates per year; 1998–2001
(n=106), 2002–2006 (n=165) and 2007–2012 (n=195). As
PCR is replacing culture for pertussis diagnosis, obtaining
sufficient strains for population studies has become difficult.
The number of participating countries for the three periods
was 7, 11 and 12, respectively (Table 2). For Finland, France,
the Netherlands and Sweden, 17 to 23 isolates were available
for each period. In contrast, for Norway and the Czech
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Republic, isolates were only available for period 2007–2012.
Table 1 shows the pertussis vaccines currently used in Euro-
pean countries.
Changes in allele frequencies
We investigated changes in frequencies of the alleles for
four proteins used in ACVs: ptxA, prn, fim2 and fim3.
The pertussis toxin promoter, ptxP, was also included, as
several previous studies have shown that the ptxP3 allele
is an important characteristic of recent clinical isolates [5,
20, 28]. Isolates were also serotyped to assess expression
of the fim2 and fim3 genes. All allelic variants discussed
here are associated with changes in protein structure. An
overview of allelic and protein variants is provided in
previously published reviews [12, 47].
For our analysis, we included data only if at least five
isolates were available in a particular period. In general,
Poland was found to be distinct, while the remaining 12
countries showed minor differences in their B. pertussis pop-
ulations. Therefore, except for the ptxA alleles and serotypes,
we limited the comparisons to Poland and pooled the remain-
ing 12 countries. All data are represented in Supplementary
Table S1.
ptxA alleles
The ACVs currently used in the European countries contain
ptxA2 and ptxA4 [12] and the Polish WCV contains only
ptxA2 [48]. Essentially, no differences were found between
the 13 countries with respect to ptxA alleles. The non-vaccine
type allele ptxA1 was identified in 428 out of the 429 isolates
analysed. One isolate, isolated in Sweden in 1998, harboured
the ptxA2 allele.
prn alleles
The ACVs currently used in the European countries contain
prn1 and prn7 [12] and the Polish WCV contains only prn1
[48]. In the group of 12 countries, four prn alleles were
observed in this study, prn1, prn2, prn3 and prn13. The
prn13 allele was detected once in Sweden during the period
1998–2001. The prn3 allele was found in all three periods but
decreased in frequency from 10 % in 1998–2001 to 4 % in
2002–2006 and to 1 % in 2007–2012. The two minor prn
alleles prn13 and prn3 were combined into one group in
Fig. 1a. In the 12 countries, prn2 predominated in 1998–
2001 with a frequency of 84 %, increasing to 91 % in 2002–
2006 and to 99 % 2007–2012 (Fig. 1a). In Poland, the fre-
quencies of prn1 in the periods 1998–2001 and 2002–2006
were, respectively, 55 and 43 % (Fig. 1b). Two Polish isolates
were available in 2007–2012, both containing prn1.
ptxP alleles
Three ptxP alleles were found in this study, ptxP1, ptxP3 and
ptxP20. ptxP20 was found once in the Czech Republic in
2007–2012 and not included in Fig. 2. An increasing preva-
lence of ptxP3 isolates was observed in the group of 12
countries from 57 % in 1998–2001 to 87 % in 2002–2006
and to 97% in 2007–2012 (Fig. 2a). In Poland, a distinct trend
was found. ptxP1 predominated in both periods 1998–2001
and 2002–2006, with frequencies of 82 and 100 %, respec-
tively (Fig. 2b). Only two Polish isolates were available in
2007–2012, both containing ptxP1.
fim2 alleles
Two fim2 alleles have been found worldwide, fim2-1 and
fim2-2 [47]. Only fim2-1 is present in the currently used ACVs
[12] and the Polish WCV [48]. In this collection, fim2-2
isolates were only detected in Poland and Belgium, while
the remaining isolates harboured the fim2-1 allele. In Belgium,
one fim2-2 isolate was observed in the period 2002–2006. In
Poland, the fim2-2 frequencies were 55 % in 1998–2001 and
43 % in 2002–2006 (Fig. 3). Only two Polish isolates were
available for the period 2007–2012: one isolate harboured the
fim2-1 allele and one harboured the fim2-2 allele; therefore,
the prevalences for the period 2007–2012were not included in
the figure.
fim3 alleles
Five fim3 alleles were found in this study, fim3-1 (found in
ACVs [12]) and the PolishWCV [48]), fim3-2, fim3-3, fim3-4
Table 2 Number of Bordetella pertussis clinical isolates used in this
study
Country 1998–2001 2002–2006 2007–2012 Total
Belgium 2 8 10 20
Czech Republic 0 0 20 20
Denmark 0 20 23 43
Finland 20 20 17 57
France 20 20 20 60
Germany 17 18 0 35
Ireland 0 5 15 20
Norway 0 0 20 20
Poland 11 7 2 20
Spain 0 2 10 12
Sweden 17 20 20 57
The Netherlands 19 23 20 62
United Kingdom 0 22 18 40
Total 106 165 195 466
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and fim3-6. Two fim3-3 isolates were found, one in the Neth-
erlands (in the period 2007–2012) and one in Denmark (in the
period 2007–2012). A fim3-4 isolate was found in France (in
the period 2007–2012) and a fim3-6 isolate was found in
Belgium (in the period 2007–2012). The three minor fim3
alleles, fim3-3, fim3-4 and fim3-6, were combined into one
group in Fig. 4a. In the group of 12 countries, fim3-1 was
found with frequencies of 50, 41 and 56 % in the periods
1998–2001, 2002–2006 and 2007–2012, respectively (Fig. 4).
In Poland, fim3-1 predominated in the period 1998–2001
(frequency 82 %) and increased in frequency to 100 % in
the period 2002–2006 (Fig. 4b). Only two Polish isolates were
available for the period 2007–2012, both containing fim3-1.
Fimbrial serotyping
B. pertussis produces two serologically distinct fimbriae, des-
ignated serotype 2 (Fim2) and serotype 3 fimbriae (Fim3). A
B. pertussis isolate may produce a single serotype or both
serotypes. Therefore, three combinations are possible: Fim2,
Fim3 and Fim2,3. Ireland and Poland were distinct with
respect to fimbrial serotypes, whereas minor differences were
found between the remaining 11 countries. Therefore, Ireland
and Poland were treated separately, while the data of the
remaining 11 countries were pooled. Fim3 predominated in
the group of 11 countries with frequencies of 69 % in 1998–
2001, 93 % in 2002–2006 and 86 % in 2007–2012 (Fig. 5a).
In Ireland, lower frequencies of Fim3 were found: 60 % in
Fig. 1 Frequencies of the prn alleles in the period 1998–2012. Isolates
were aggregated in three periods, 1998–2001, 2002–2006 and 2007–
2012. a Allele frequencies in the 12 pooled countries: Belgium, the
Czech Republic, Denmark, Finland, France, Germany, Ireland, Norway,
Spain, Sweden, the Netherlands and the United Kingdom. b Allele
frequencies in Poland. Due to the limited availability of Polish isolates
in the period 2007–2012 (n=2), no data are included for this period. The
percentages and number of strains analysed in the different periods are
indicated
Fig. 2 Frequencies of the ptxP alleles in the period 1998–2012. See
caption of Fig. 1 for further details
Fig. 3 Frequencies of the fim2 alleles in the period 1998–2006 in Poland.
Two periods are indicated, 1998–2001 and 2002–2006. Due to the limited
availability of Polish isolates in 2007–2012 (n=2), no data are included
for this period. In the remaining 12 countries, only fim2-1 was observed,
with the exception of Belgium, where one fim2-2 isolate was identified
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2002–2006 and 40 % in 2007–2012. No Irish isolates were
available for the period 1998–2001 (Fig. 5b). In Poland, Fim2
predominated in 1998–2001 and 2006–2006 (frequencies of
73 and 100%, respectively) (Fig. 5c). Only two Polish isolates
were available in 2007–2012, both of which were Fim2. The
Polish WCV is derived from strains which produce both Fim2
and Fim3 [49]. One strain, isolated in Spain in 2010, was
found to be auto-agglutinable (data not shown).
Multi-locus variable-number tandem repeat analysis (MLVA)
Thirty-four MLVA types (MTs) were found in the 13 coun-
tries. MTs that were found less than five times in the group of
12 countries or in Poland were combined and designated as
group R in Fig. 6a, b. MT27 predominated in the group of 12
countries (frequencies from 54 to 100 % per country) but was
found once in Poland (in 1994–2001). MT27 predominated in
1998–2001, with a frequency of 49 %, which increased to
86 % in 2002–2006 and decreased to 74 % in 2007–2012
(Fig. 6a). MT29 predominated only in 1998–2001, with a
frequency of 22 %, which decreased to 0 % in 2002–2006
and increased slightly to 1 % in 2007–2012. MT78 predom-
inated in Finland in 2007–2012 (data not shown) (frequency
53 %). MT78 was found once in Norway (in the period 2007–
2012) and once in Germany (in the period 1998–2001). In
Poland, MT70 predominated, with frequencies of 55 % in
1998–2001 and 14% in 2002–2006 (Fig. 6b). Besides Poland,
MT70 has been found once in Belgium in the period 2002–
2006. During the period 2002–2006, MT29 predominated in
Poland, with a frequency of 57 %.
Pulsed-field gel electrophoresis (PFGE)
Eighty-seven PFGE types were found in the 13 countries.
PFGE types that were found less than five times in the group
of 12 countries were combined and designated as group R in
Fig. 7a. In the group of 12 countries, increasing frequencies
were observed for BpSR3 (0 % in 1998–2001 to 23 % in
2007–2012) and BpSR10 (10 % in 1998–2001 to 19 % in
2007–2012). Decreasing trends have been found for BpSR11
(29 % in 1998–2001 to 13 % in 2007–2012). No differences
Fig. 4 Frequencies of the fim3 alleles in the period 1998–2012. See
caption of Fig. 1 for further details
Fig. 5 Frequencies of the serotypes in the period 1998–2012. a Serotype
frequencies of the 11 pooled countries; Belgium, the Czech Republic,
Denmark, Finland, France, Germany, Norway, Spain, Sweden, the
Netherlands and the United Kingdom. b Serotype frequencies in
Ireland. c Serotype frequencies in Poland. See caption of Fig. 1 for details
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were found for the frequencies of BpSR5 (7 % in 1998–2001,
9% in 2002–2006 and 11% in 2007–2012) and BpSR12 (4%
in 1998–2001, 8 % in 2002–2006 and 5 % in 2007–2012)
(Fig. 7a). In Poland, BpSR23 predominated in the period
1998–2001 (frequency 46 %). The predominating PFGE type
in Europe, BpSR11, was found once in Poland, in the period
1998–2001 (Fig. 7b).
Discussion
In this study, we analysed B. pertussis isolates from 13 Euro-
pean countries during the period 1998–2012. In general, our
comparison showed that 12 countries had very similar
B. pertussis populations (Belgium, the Czech Republic, Den-
mark, Finland, France, Germany, Ireland, the Netherlands,
Norway, Spain, Sweden and the United Kingdom), while
Poland was quite distinct. As noted previously, in all
countries, circulating isolates were distinct from vaccine
strains with respect to one or more of the investigated
antigens [2, 15–25].
The ptxA gene was found to be highly monomorphic and,
with one exception, all circulating isolates carried the non-
vaccine type allele ptxA1. Three ptxP alleles were observed in
this collection of isolates, ptxP1, ptxP3 and ptxP20. A notable
observation was the low percentage of ptxP3 isolates in Po-
land (10 %, n=20) compared to the other countries (average
72 %, range 37–100 %). Interestingly, the two Polish ptxP3
isolates were found in the first period, 1998–2001, but not in
the later periods. Possibly, ptxP3 isolates do not have a fitness
advantage in Poland, in contrast to the other 12 countries.
Further, although the non-vaccine type allele prn2 was found
at frequencies of 45 and 57 % in the periods 1998–2001 and
2002–2006 in Poland, respectively, these percentages were
lower than those observed in the remaining 12 countries
(average 83 %, range 37–100 %). Comparing the clinical
outcome between ptxP1- and ptxP3-infected individuals, es-
pecially in Poland, would be useful.
In Poland, two fim2 alleles circulated in approximately
equal frequencies, fim2-1 (the vaccine type in Poland) and
fim2-2. In contrast, in the remaining countries, only fim2-1
was observed, with the exception of Belgium, where a single
fim2-2 isolate was identified. The Belgian fim2-2 isolate was
linked to the same MLVA and PFGE type (MT70 and
BpBGR4, respectively) as 30 % of the Polish fim2-2 isolates,
suggesting that the fim2-2 isolate was introduced in Belgium
from Poland. The fim2-2 allele was also observed in the pre-
Fig. 6 Frequencies of the predominating multi-locus variable-number
tandem repeat analysis (MLVA) types in the period 1998–2012. See
caption of Fig. 1 for further details
Fig. 7 Frequencies of the predominating pulsed-field gel electrophoresis
(PFGE) types in the period 1998–2012. See caption of Fig. 1 for further
details
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vaccination era in the Netherlands (57 %, n=7), while all
isolates from 1965 or later harboured fim2-1 [45]. More re-
cently, fim2-2 isolates were observed in Moscow (89 % in the
period 1990–2004) and Australia (36 % in the period 1998–
2008) [50, 51]. In both Poland and Australia, a significant
percentage of the fim2-2 isolates were linked toMT70 (80 and
88 %, respectively), possibly suggesting a common origin.
However, independent genesis and fixation of the fim2-2
single nucleotide polymorphism (SNP) by different
B. pertussis lineages may also be possible. The latter would
suggest that the mutation has a significant effect on fitness.
The limited distribution of fim2-2 isolates in Europe compared
to Moscow and Poland could be due to geographic isolation, as
travelling to Poland and/or Moscow from Western Europe was
restricted until the late 1980s. However, in the Czech Republic,
which was also located in the former Eastern Europe, no fim2-2
isolates have been observed. Another cause for the observation
that the distribution of fim2-2 isolates was limited to Poland and
Russia could be the use of the pertussis vaccines, as in Poland
and Moscow, a WCV is still used, while an ACV has already
been introduced in the Czech Republic in 2007.
The Polish and Irish populations showed higher Fim2
frequencies compared to the other 11 countries (80 and
30 %, respectively). An association between Fim2 and the
prevalence of fim2-2 isolates has been found previously in the
United Kingdom, where isolates collected between 1920 and
2002 were studied [52]. All isolates with the fim2-2 allele (n=
20) were Fim2. This was also observed in Poland, where 90%
of the fim2-2 isolates were Fim2. However, no fim2-2 alleles
have been found in Ireland in this study.
MT27 is the predominating MT in Europe. Previous Euro-
pean studies showed a linkage between ptxP3 and MT27 [17,
18, 46]. Indeed, 97% ofMT27 isolates in this study harboured
the ptxP3 allele. MT27 was also the predominating MT in
countries outside Europe, including Australia [2], Japan [25]
and the United States [22]. One of the two Polish ptxP3
isolates was also typed as MT27.
The Fim and Prn types of Danish isolates were similar to
the isolates found in other countries, except Poland. Since the
Danish vaccine contains only Ptx, the changes to the Fim and
Prn types in Danish isolates may be the result of overflow
from neighbouring countries, rather than selective pressure
from the Ptx vaccine.
Five predominant PFGE types have been found in Europe,
BpSR3, BpSR5, BpSR10, BpSR11 and BpSR12 [43]. These
PFGE types were also predominant in at least one Canadian
province, where 317 out of 434 (73 %) isolates collected
between 1998 and 2006 belonged to the PFGE types BpSR5,
BpSR11 and BpSR12 [24]. However, no isolate with PFGE
types BpSR3 and BpSR10 have been found in Canada so far,
suggesting some geographic differences in isolates.
The present study showed minor differences in European
countries which used ACVs based on MAST, fimbrial
serotyping, MLVA and PFGE. However, Poland, the only
country included in this study where a WCV is still used,
showed a distinct population.
A distinct population compared to Europe has also been
found in Serbia, where a WCV has been continued to be used
since 1957 [53]. Both countries, Poland and Serbia, have a
vaccination history including several changes of strain com-
positions since the 1960s, which could explain the distinct
B. pertussis populations compared to the European countries
where an ACV is used. The Polish and Serbian B. pertussis
populations both show high prn1 frequencies, 43 % in 2002–
2006 and 47 % in 1985–2000, respectively [43], compared to
high prn2 frequencies (>90 %) in European countries, where
ACVs have been used for many years.
The immune response induced by the two vaccines is
different. WCVs induce a broad immune response, but with
relatively low titres, whereas ACVs induce high titres against
only a few antigens. Theoretical studies suggest that a change
from a broad to a narrow immune response will favour the
emergence of escape variants [54]. Indeed, several studies
have shown the emergence of Prn-deficient strains in popula-
tions where ACVs are used [7, 31–39]. This is in contrast with
Poland and Serbia, where a WCV has been used for many
years. No Prn-deficient strains have been detected in both
countries [48, 53].
This study has some limitations. Isolates were not sampled
randomly and the sample size from some countries was small.
However, as culture is being replaced by PCR, less and less
isolates are available for typing and most members of this
study sent all isolates available. Further, it was not possible to
establish relationships between strain type and vaccination
status, as very limited vaccination data were available. Fur-
ther, FHA, also a component in some ACVs, was not includ-
ed, as the large size of the gene precluded analyses. Interest-
ingly, FHA-deficient isolates have been described [32]. In the
future, targeted sequencing of genes for vaccine antigens may
be replaced by whole genome sequencing, which may reveal
other relevant loci to be included in MAST [51, 55]. This
study was not set up to identify isolates not producing Prn in
Europe, as a recent study has already addressed this issue [38].
Overall, low prevalences (<4 %) of Prn-deficient strains were
found, except in Norway and France (25 % in 2007–2009 and
15 % in 2013, respectively [56]).
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